Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact on +44 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Testimonials
I was very happy with the recruitment process all the way through from start to end. Thank you for all the hard work and effort Zenopa put in.
Raspal, 2012

Eisai licenses ChemAxon software for drug discovery

4 January 2012 00:00 in Pharmaceutical Company Product News


Eisai has bolstered its drug development pipeline through a new licensing deal for the use of ChemAxon software for clinical data management.

Patcore, the Japan-based agency for ChemAxon, has licensed the JChem Cartridge for Oracle software to the pharmaceutical company, allowing it to take advantage of new database storage and search technology.

The system is designed for the management of chemical structure information generated in discovery processes and aims to deliver faster performance, improved accuracy and greater flexibility than alternative solutions.

At the same time, Eisai will also be rolling out Patcore's structure compound control checking system CRAIS Checker - which it currently uses in its Japanese laboratories - on a global scale.

This software has been adopted by the majority of Japanese pharmaceutical companies and allows users to correctly identify controlled substances more efficiently and confidently.

Last month, Eisai augmented its research capabilities further by commencing operations at its new H3 Biomedicine research facility in Massachusetts.ADNFCR-8000103-ID-801254533-ADNFCR

Other news stories from 04/01/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd